Code: 04900892

Evaluating Pharmaceuticals for Health Policy and Reimbursement

Name: Evaluating Pharmaceuticals for Health Policy and Reimbursement
Brand: BMJ Publishing Group
SKU: 04900892
Price: 131.57 EUR
Availability: InStock

by Nick Freemantle

Language: English
Binding: Paperback
Number of pages: 280
Publisher: BMJ Publishing Group, 2004
More about this

131.57 €

Low in stock at our supplier
Shipping in 14 - 18 days

Potřebujete více kusů?Máte-li zájem o více kusů, prověřte, prosím, nejprve dostupnost titulu na naši zákaznické podpoře.

Add to wishlist

Modern Electronic Structure Theory - Part Ii
168.52 €
Buy
Nervous Acts
122.92 €
Buy
Systematic Methodology for Real-Time Cost-Effective Mapping of Dynamic Concurrent Task-Based Systems on Heterogenous Platforms
120.80 €
Buy

Give this book as a present today

Order book and choose Gift Order.
We will send you book gift voucher at once. You can give it out to anyone.
Book will be send to donee, nothing more to care about.

Book gift voucher sample Read more

More about Evaluating Pharmaceuticals for Health Policy and Reimbursement

Book details
Synopsis
Trending among others

You get 331 loyalty points

Book synopsis

"The challenge in all settings is to make the difficult decisions in a way that is defensible, justifiable, ethical, and equitable"So write Nick Freemantle and Suzanne Hill in their introduction to this important discussion on decision making in the reimbursement of pharmaceuticals. Based around a programme supported by the World Health Organization, chapters by leading academics involved in the research tackle such major issues as international pharmaceutical policy, tensions in licensing policies, priority setting, and relationships between the stakeholders.Chapters include- Development of marketing authorisation procedures for pharmaceuticals- Interpreting clinical evidence- International pharmaceutical policy: health creation or wealth creation?- Development of fourth hurdle policies around the world- Economic modelling in drug reimbursement- Priority setting in health care: matching decision criteria with policy objectives- Tensions in licensing and reimbursement decisions: case of riluzole for amytrophic lateral sclerosis- Relationship between stakeholders: managing the war of words- Medicine and the media: good information or misleading hype?- How to promote quality use of cost-effective medicines- Using economic evaluation to inform health policy and reimbursement: making it happen and making it sustainable- Pricing of pharmaceuticals- Evaluating pharmaceuticals for health policy in low and middle income country settings.Besides the controversial issues there is a wealth of practical information including economic modelling and the experiences from the WHO programme, providing readers with workable examples. This is essential reading for clinical researchers in pharmaceuticalsand policy makers everywhere.